crpc — TargetMol Chemicals

Cat No.	Product Name	Synonyms	Targets
T6889	MI-136		Apoptosis , Epigenetic Reader Domain , Androgen Receptor
	MI-136 inhibits expression of androgen receptor (AR) target genes that DHT induced.		Apoptosis , Epigenetic Reader Domain , Androgen Receptor
T6258	Zibotentan	ZD4054	Apoptosis , Endothelin Receptor
	Zibotentan (ZD4054) (ZD4054) is a specific Endothelin (ET)A antagonist with IC50 of 21 nM, exhibiting no activity at ETB. Phase 3.		Apoptosis , Endothelin Receptor
T38684	AKR1C3-IN-4	AKR1C3-IN-4	NADPH
	AKR1C3-IN-4 is a potent and selective inhibitor of aldo-keto reductase 1C3 (AKR1C3) with an IC50 of 0.56 μM. AKR1C3-IN-4 has the potential for castrate resistant prostate cancer (CRPC) research.		NADPH
T9246	JNJ-63576253		Androgen Receptor
	JNJ-63576253 is a Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC).		Androgen Receptor
T36841	IPI-9119		Fatty Acid Synthase
	IPI-9119 is an orally active, selective and irreversible FASN inhibitor (IC50 = 0.3 nM).		Fatty Acid Synthase
T9446	KB-0742 dihydrochloride		CDK
	KB-0742 dihydrochloride is a potent, selective and orally inhibitor of CDK9.		CDK
T8933	JNJ-63576253 free base	TRC253,JNJ-63576253	Androgen Receptor
	JNJ-63576253 free base (TRC253) is a potent and orally active full antagonist of androgen receptor (AR), with IC50s of 37 and 54 nM for F877L mutant AR and wild-type AR in LNCaP cells. JNJ-63576253 can be used for the re...		Androgen Receptor
T2895	Lupeol	Fagarasterol,Monogynol B,Clerodol,(3β,13ξ)-Lup-20(29)-en-3-ol,Farganasterol	Apoptosis , Androgen Receptor , Akt
	Lupeol (Monogynol B) is a novel androgen receptor inhibitor with anti-inflammatory and antioxidant activity.		Apoptosis , Androgen Receptor , Akt
T28502	Ralaniten	EPI-002	Androgen Receptor
	Ralaniten (EPI-002) is a potent, specific, and orally active antagonist of the androgen receptor N-terminal structural domain (AR-NTD).Ralaniten inhibits AR transcriptional activity with an IC50 value of 7.4 μM.Ralanites...		Androgen Receptor
T39954	AU-15330		Epigenetic Reader Domain , PROTACs
	AU-15330 is a protein hydrolysis-targeted chimeric (PROTAC) degrader of the SWI/SNF ATPase subunits SMARCA2 and SMARCA4.AU-15330 potently inhibits tumor growth in a prostate cancer xenograft model and acts synergisticall...		Epigenetic Reader Domain , PROTACs
T76758	Rilotumumab	AMG 102	c-Met/HGFR
	Rilotumumab (AMG 102) is a monoclonal antibody targeting hepatocyte growth factor that inhibits HGF/ MET-driven signaling. Rilotumumab has antitumor effects and can be used to study castration-resistant prostate cancer (...		c-Met/HGFR
T16807	Rucaparib monocamsylate	Rucaparib Camsylate	PARP
	Rucaparib monocamsylate (Rucaparib Camsylate) is a PARP inhibitor (PARP1,Ki of 1.4 nM). Rucaparib Camsylate also displays binding affinity to eight other PARP domains.		PARP
T9005	VPC-80051 racemate		Others
	VPC-80051 is the first small molecule inhibitor of hnRNP A1 splicing activity by using a computer-aided drug discovery approach.		Others
T7752	(S,R,S)-AHPC-Me	VHL ligand 2,E3 ligase Ligand 1A	Ligand for E3 Ligase
	(S,R,S)-AHPC-Me (E3 ligase Ligand 1A) (VHL ligand 2) is the (S,R,S)-AHPC-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein[1]. (S,R,S)-AHPC-Me can be used to synthesize ARV-771. ARV-771 is a...		Ligand for E3 Ligase
T6127	Rucaparib Phosphate	AG-014699 phosphate,PF-01367338,AG-014699,PF-01367338 phosphate	PARP
	Rucaparib Phosphate (PF-01367338 phosphate) is an inhibitor of PARP (Ki: 1.4 nM for PARP1) that is used in clinical therapy to sensitize cancer cells to chemotherapy.		PARP
T4463	Rucaparib	AG-14447,PF-01367338,AG014699	PARP
	Rucaparib (PF-01367338) is an inhibitor of PARP with Ki of 1.4 nM for PARP1 in a cell-free assay, and also shows binding affinity to eight other PARP.		PARP
T82326	Genkwadaphnin
	Genkwadaphnin, a daphnane diterpenoid, targets importin-β1, reducing the nuclear accumulation of CRPC drivers and suppressing downstream oncogenic signaling. Demonstrating potent anti-tumor effects, it inhibits castratio...
T61653	VPC-13789
	VPC-13789 is a highly potent, selective, and orally bioavailable antiandrogen compound that shows promise for studying and developing therapeutics for castration-resistant prostate cancer (CRPC). In LNCaP cells, VPC-1378...
T64289	Rucaparib camsylate
	Rucaparib (AG014699) camsylate is an orally active inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a Ki=1.4 nM for PARP-1. Rucaparib camsylate is an inhibitor of hexose hexaphosphate dehydrogenase (H6PD). Ruc...
T70847	BMS-351
	BMS-351 is a potent and selective, nonsteroidal CYP17A1 lyase inhibitor with robust selectivity over steroidogenic CYPs 21A2 and 11B1. BMS-351 emerges as an outstanding preclinical candidate to treat CRPC and is likely t...